Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Anticoagulation management and outcomes in cancer-associated ovarian and renal vein thrombosis: A multicenter retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

EBElena ButeraRTRosa TalericoMCMarc Carrier

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reports 3.8% recurrent venous thromboembolism incidence in patients with cancer-associated ovarian and renal vein thrombosis, suggesting effective anticoagulation management

Key Points

  • The overall incidence of recurrent venous thromboembolism was 3.8% at both 6 and 12 months, indicating effective management in cancer patients.
  • Patients with cancer-associated venous thromboembolism mostly received anticancer therapy, with 80% treated using therapeutic anticoagulation.
  • Analysis utilized confidence intervals to assess outcomes of major bleeding events, which occurred in only 2.5% of patients within the first 6 months.
  • Findings support the notion that anticoagulation for ovarian and renal vein thrombosis is associated with a modest bleeding risk among cancer patients.

Cite This Study

Butera et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e251https://doi.org/10.1182/blood-2025-4906
View Full Paper
Ask AI
Bookmark
Share